Skip to content
BiologicalX

Comparison

DHEA vs Omega-3 (EPA/DHA)

Side-by-side of DHEA and Omega-3 (EPA/DHA). Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

DHEA

  • Adrenal androgen precursor; serum DHEA-S declines progressively after the third decade of life
  • OTC dietary supplement in US under DSHEA 1994; prescription in EU, UK, Canada, Australia
  • FDA approved as Intrarosa (6.5 mg vaginal insert) for postmenopausal dyspareunia in 2016
  • Acts as tissue-specific prohormone converted intracrinologically to testosterone and estrogens
  • Best evidence: adrenal insufficiency replacement and vaginal atrophy; weaker on cognition and longevity
  • WADA banned in competitive sport; banned in NCAA, MLB, NFL, IOC settings

Omega-3 (EPA/DHA)

  • Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
  • REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
  • Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
  • Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
  • Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
  • Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state

Side-by-side

Attribute DHEA Omega-3 (EPA/DHA)
Category hormone supplement
Also known as dehydroepiandrosterone, prasterone, Intrarosa fish oil, EPA, DHA, marine omega-3
Half-life (hr) 12 48
Typical dose (mg) 25 2000
Dosing frequency daily, typically morning 1 to 2 times daily with food
Routes oral, vaginal, topical oral
Onset (hr) 1 4
Peak (hr) 1 12
Molecular weight 288.42 302.45
Molecular formula C19H28O2 C20H30O2 (EPA); C22H32O2 (DHA)
Mechanism Steroid prohormone converted intracrinologically to testosterone and estrogens in target tissues; also exerts direct effects via sigma-1 receptor, GABA-A modulation, and glucocorticoid receptor interaction. Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function.
Legal status OTC supplement in US (DSHEA 1994); prescription in EU, UK, Canada, Australia Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia
WADA status banned allowed
DEA / Rx OTC supplement in US (not scheduled); Rx in EU, UK, Canada, Australia Not scheduled
Pregnancy Contraindicated in pregnancy Recommended at 200 to 600 mg DHA/day for fetal development
CAS 53-43-0 10417-94-4
PubChem CID 5881 446284
Wikidata Q411733 Q207688

Safety profile

DHEA

Common side effects

  • acne
  • oily skin
  • hirsutism (women)
  • gynecomastia (men, higher doses)
  • irritability
  • insomnia

Contraindications

  • hormone-sensitive cancer (breast, ovarian, prostate)
  • active liver disease
  • uncontrolled lipid disorder
  • pregnancy and lactation

Interactions

  • warfarin: case reports of altered INR; monitor(moderate)
  • estrogens (HRT): additive estrogenic effect via conversion; monitor(moderate)
  • insulin: may improve insulin sensitivity slightly; monitor glucose(minor)
  • anastrozole: may reduce DHEA-derived estrogen; clinical relevance unclear(minor)

Omega-3 (EPA/DHA)

Common side effects

  • fishy aftertaste
  • eructation (fish burps)
  • mild dyspepsia
  • loose stools at high doses

Contraindications

  • fish allergy (use algal omega-3 alternative)
  • active bleeding disorders
  • scheduled surgery (discontinue 5-7 days prior)

Interactions

  • warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
  • aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
  • statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
  • antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)

Which Should You Take?

Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. DHEA is the right call when one of the conditionals below applies.

  • If your priority is hormonal optimization, pick DHEA.
  • If your priority is cardiovascular health, pick Omega-3 (EPA/DHA).
  • If your priority is focus or working memory, pick Omega-3 (EPA/DHA).

Edge case: DHEA is contraindicated in pregnancy; Omega-3 (EPA/DHA) is the safer pick if that applies.

Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for DHEA only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between DHEA and Omega-3 (EPA/DHA)?

DHEA and Omega-3 (EPA/DHA) differ in category (hormone vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, DHEA or Omega-3 (EPA/DHA)?

DHEA half-life is 12 hours; Omega-3 (EPA/DHA) half-life is 48 hours.

Can you stack DHEA with Omega-3 (EPA/DHA)?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper